IRVINE, Calif., Dec. 6, 2006 (PRIME NEWSWIRE) -- Millennium Biotechnologies (OTCBB:MBTG) is proud to announce that it is an active participant in the Banned Substance Control Group's (BSCG) certification program. This is the only certification program in the U.S. that uses a World Anti Doping Agency accredited laboratory to detect for dangerous banned substances in nutritional supplements. Each batch of Millennium's line of Resurgex products are now tested and certified not to contain substances such as hormones, steroids, stimulants, diuretics, etc. that are banned for professional and collegiate sports. "By participating in this program, we provide our Resurgex consumers greater confidence that we are taking all precautions to ensure that harmful anabolic agents and stimulants are not in our products," states Carl Germano, RD, CNS, CDN Vice President of Research & Product Development for Millennium Biotechnologies. "The consumer and athlete can now be assured that our Resurgex line of products can be safely consumed as each batch is tested for a list of substances that are banned by organizations such as the International Olympic Committee (IOC), the World Anti-Doping Agency (WADA), the United States Anti-Doping Agency (USADA), the National Collegiate Athletic Association (NCAA), the National Football League (NFL), and many other professional and amateur sports leagues."
With over 5 years in the medical market as a nutritional adjunct to medical care for immunocompromised conditions and several successful studies including 2 double blind, placebo controlled trials in Division 1 athletes, the Resurgex line of products are breaking new ground for credibility and professionalism in the sports nutrition sector. The final set of results from Millennium's sponsored Division 1 Football trial at Rutgers University have shown that Resurgex had a significant effect on recovery markers including testosterone:cortisol ratios compared to a popular sports beverage on the market. "Along with our previous statistically significant improvements in body composition and strength parameters, the recovery marker data continues to validate Resurgex as an important nutritional adjunct for the athlete," states Mr. Germano. "As we have seen in the medical market, Resurgex is now able to offer the athlete a product that will assist in recovery in efforts to improve performance. In addition, our participation in the BSCG program continues to set us apart from the competition."
About Millennium Biotechnologies, Inc.
Millennium Biotechnologies, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products, RESURGEX(r), RESURGEX Plus(r), and RESURGEX Select(r), are designed to assist in reducing fatigue and oxidative stress, maintaining lean muscle and immune support in immunocompromised conditions. In addition, Resurgex products were developed to address the multiple nutritional needs of professional athletes as well as those who are involved in regular exercise programs. Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly-traded company (OTCBB:MBTG). For more information about Millennium Biotechnologies, please call Frank Guarino, Chief Financial Officer, at FGuarino@Milbiotech.com or call (908) 604-2500. For more information about the Resurgex line of products visit http://www.resurgex.com.
Millennium plans to file with the Securities and Exchange Commission and mail to its stockholders a proxy statement which will contain information about Millennium, the sale of its assets and the formation and capitalization of RAC Nutrition (the "Proposed Transaction") and related matters. Stockholders are urged to read the proxy statement carefully when it is available, as it will contain important information that stockholders should consider before making a decision about the Proposed Transaction. In addition to receiving the proxy statement from Millennium by mail, stockholders also will be able to obtain the proxy statement, as well as other filings containing information about Millennium, without charge, from the Securities and Exchange Commission's website (http://www.sec.gov). This announcement is neither a solicitation of proxy, an offer to purchase, nor a solicitation of an offer to sell shares of Millennium. Millennium and its executive officers and directors may be deemed to be participants in the solicitation of proxies from Millennium's stockholders with respect to the Proposed Transaction. Information regarding any interests that Millennium's executive officers and directors may have in the Proposed Transaction will be set forth in the proxy statement.
This release includes certain forward-looking information that is based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of our products and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.